Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 5Completed 5Unknown 2Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 223Cyclophosphamide 192Radiotherapy 183Nivolumab 181Carboplatin 153Cisplatin 114Paclitaxel 112Dexamethasone 110Radiosurgery 103Magnetic Resonance Spectroscopy 97Surveys and Questionnaires 90Ipilimumab 81Doxorubicin 79Lenalidomide 76Rituximab 75durvalumab 74atezolizumab 72Radiation 72fludarabine 68Standard of Care 68Gemcitabine 68venetoclax 67Specimen Handling 65Etoposide 64Capecitabine 64Bevacizumab 62Oxaliplatin 59Docetaxel 58Biopsy 58Radiotherapy, Intensity-Modulated 56

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × OTHER × Infusions, Intravenous × Clear all
NCT06505837 2025-08-28

JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer(NSCLC)

Shanghai Junshi Bioscience Co., Ltd.

Phase 3 Active not recruiting
395 enrolled
Thoracic

Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer

NCT05894889 2025-07-23

Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC

Peking University

Phase 2 Active not recruiting
70 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡